[go: up one dir, main page]

IS8248A - Útskipt tvíketópíperasín og notkun þeirra sem oxytósínmótlyfja - Google Patents

Útskipt tvíketópíperasín og notkun þeirra sem oxytósínmótlyfja

Info

Publication number
IS8248A
IS8248A IS8248A IS8248A IS8248A IS 8248 A IS8248 A IS 8248A IS 8248 A IS8248 A IS 8248A IS 8248 A IS8248 A IS 8248A IS 8248 A IS8248 A IS 8248A
Authority
IS
Iceland
Prior art keywords
tweketopiperazine
replacement
oxytocin antagonists
oxytocin
antagonists
Prior art date
Application number
IS8248A
Other languages
English (en)
Other versions
IS2463B (is
Inventor
Liddle John
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS8248A publication Critical patent/IS8248A/is
Publication of IS2463B publication Critical patent/IS2463B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IS8248A 2003-06-24 2006-01-20 Útskipt díketópíperasín og notkun þeirra sem oxytósínmótlyfja IS2463B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0314738A GB0314738D0 (en) 2003-06-24 2003-06-24 Novel compounds
PCT/EP2004/006814 WO2005000840A1 (en) 2003-06-24 2004-06-22 Substituted diketopiperazines and their use as oxytocin antagonists

Publications (2)

Publication Number Publication Date
IS8248A true IS8248A (is) 2006-01-20
IS2463B IS2463B (is) 2008-11-15

Family

ID=27637257

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8248A IS2463B (is) 2003-06-24 2006-01-20 Útskipt díketópíperasín og notkun þeirra sem oxytósínmótlyfja

Country Status (30)

Country Link
US (6) US8071594B2 (is)
EP (1) EP1641787B1 (is)
JP (1) JP5128126B2 (is)
KR (1) KR101131378B1 (is)
CN (2) CN100404532C (is)
AR (1) AR044869A1 (is)
AT (1) ATE361295T1 (is)
AU (1) AU2004251868B2 (is)
BR (1) BRPI0411729A (is)
CA (1) CA2530310C (is)
CY (1) CY1107703T1 (is)
DE (1) DE602004006268T2 (is)
DK (1) DK1641787T3 (is)
EG (1) EG24929A (is)
ES (1) ES2285474T3 (is)
GB (1) GB0314738D0 (is)
HR (1) HRP20070286T3 (is)
IL (1) IL172529A (is)
IS (1) IS2463B (is)
MA (1) MA27887A1 (is)
MX (1) MXPA05014068A (is)
MY (1) MY140653A (is)
NO (1) NO332677B1 (is)
NZ (1) NZ544006A (is)
PL (1) PL1641787T3 (is)
PT (1) PT1641787E (is)
RU (1) RU2343152C2 (is)
TW (1) TWI340745B (is)
WO (1) WO2005000840A1 (is)
ZA (1) ZA200509890B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0314738D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
US8716286B2 (en) 2009-10-30 2014-05-06 Glaxo Group Limited Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione
CN106999497A (zh) 2014-06-16 2017-08-01 葛兰素史密斯克莱知识产权发展有限公司 用于治疗早产的瑞托西班
PT3397622T (pt) 2016-01-04 2022-06-15 ObsEva SA Co-administração de alfa-amino éster de derivado de hidroxipropiltiazolidina e carboxamida e um agente tocolítico
JP7036791B2 (ja) 2016-07-21 2022-03-15 オブセヴァ エス．エー． 胚着床を促進し、流産を防ぐためのオキシトシンアンタゴニスト投与レジメン
CN106674031A (zh) * 2016-11-18 2017-05-17 浙江工业大学 R‑2‑二氢茚氨酸的制备方法
JP7584201B2 (ja) 2019-09-03 2024-11-15 オブセヴァ エス．エー． 薬学的組成物
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
US5091387A (en) * 1990-03-02 1992-02-25 Merck & Co., Inc. Spirocyclic oxytocin antagonists
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
GB2326639A (en) * 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
US5968938A (en) * 1997-06-18 1999-10-19 Merck & Co., Inc. Piperazine oxytocin receptor antagonists
BR9907300A (pt) 1998-01-27 2000-10-24 Aventis Pharm Prod Inc Inibidores do fator xa oxoaza-heterociclila substituìdos
SK10642000A3 (sk) 1998-01-29 2001-07-10 Aventis Pharmaceuticals Products Inc. Spôsob prípravy n-[(alifatickej alebo aromatickej)karbonyl)]-2- aminoacetamidovej zlúčeniny a cyklizovanej formy tejto zlúčeniny
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
GB2372740A (en) 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
US20030229001A1 (en) 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
GB0314738D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
EP2760473A1 (en) 2011-09-27 2014-08-06 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas

Also Published As

Publication number Publication date
US8357685B2 (en) 2013-01-22
EP1641787A1 (en) 2006-04-05
AU2004251868A1 (en) 2005-01-06
MA27887A1 (fr) 2006-05-02
RU2006101859A (ru) 2006-06-10
US8071594B2 (en) 2011-12-06
IL172529A (en) 2011-06-30
US20160074413A1 (en) 2016-03-17
IL172529A0 (en) 2006-04-10
NO332677B1 (no) 2012-12-03
ES2285474T3 (es) 2007-11-16
CN1812987A (zh) 2006-08-02
NO20060383L (no) 2006-01-24
GB0314738D0 (en) 2003-07-30
EP1641787B1 (en) 2007-05-02
MXPA05014068A (es) 2006-03-02
BRPI0411729A (pt) 2006-08-08
US20150105387A1 (en) 2015-04-16
JP2009513484A (ja) 2009-04-02
TWI340745B (en) 2011-04-21
CA2530310C (en) 2012-01-03
AR044869A1 (es) 2005-10-05
RU2343152C2 (ru) 2009-01-10
KR101131378B1 (ko) 2012-04-04
PL1641787T3 (pl) 2007-08-31
US20140058105A1 (en) 2014-02-27
ZA200509890B (en) 2006-07-26
HK1088910A1 (en) 2006-11-17
JP5128126B2 (ja) 2013-01-23
US20070149524A1 (en) 2007-06-28
CA2530310A1 (en) 2005-01-06
DE602004006268T2 (de) 2008-01-10
US20120004229A1 (en) 2012-01-05
TW200524917A (en) 2005-08-01
US20130102783A1 (en) 2013-04-25
CN100404532C (zh) 2008-07-23
PT1641787E (pt) 2007-08-01
MY140653A (en) 2010-01-15
IS2463B (is) 2008-11-15
US8937179B2 (en) 2015-01-20
KR20060024440A (ko) 2006-03-16
WO2005000840A1 (en) 2005-01-06
US9452169B2 (en) 2016-09-27
CN101597282A (zh) 2009-12-09
DK1641787T3 (da) 2007-09-17
ATE361295T1 (de) 2007-05-15
CY1107703T1 (el) 2013-04-18
EG24929A (en) 2011-01-05
WO2005000840A8 (en) 2005-05-19
NZ544006A (en) 2008-12-24
AU2004251868B2 (en) 2009-01-22
HRP20070286T3 (en) 2007-08-31
DE602004006268D1 (de) 2007-06-14

Similar Documents

Publication Publication Date Title
IL189602A0 (en) Indenoisoquinolinone analogs and methods of use thereof
DE60332321D1 (de) Ultrafeine zusammensetzungen von formoterol
IL182734A0 (en) 4-aminotetracyclines and methods of use thereof
EP1855833A4 (en) PLASMATA AND METHOD OF USE THEREOF
GB0404124D0 (en) Antagonists of GIP
EP1680535A4 (en) METHODS AND COMPOSITIONS FOR GALVANOPLASTY
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
JP2006502186A5 (ja) β-グルカンの使用
IS8248A (is) Útskipt tvíketópíperasín og notkun þeirra sem oxytósínmótlyfja
AU2003277215A8 (en) Novel neurokinin antagonists and methods of use thereof
EP1789437A4 (en) INHIBITORS OF NPC1L1 AND NPC1L1 AND METHODS OF USE THEREOF
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
PL379702A1 (pl) Pochodne benzamidu jako agoniści oksytocyny i antagoniści wazopresyny
EP1838730A4 (en) PAN-HER ANTAGONISTS AND METHODS OF USE
ATE432703T1 (de) Substituierte phenylacetamide und ihre anwendung als protease inhibitoren
DE602004024640D1 (de) Reinigung von titantetrachlorid
FR2843451B1 (fr) Fronde du type lance-pierres
EP1809060A4 (en) COMMUNICATION PROGRAM AND COMMUNICATION TERMINAL
SE0301596D0 (sv) New methods and use
SE0403161D0 (sv) Ny användning av glucosine
TW582574U (en) Structure of portable expanding-device
SE0400613D0 (sv) New compounds and use thereof
SE0301887D0 (sv) New use VI
UA9216S (uk) Комплект патерлиць і хреста
SE0300730D0 (sv) New Landmarks and Use Thereof